Sterling Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Sterling Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35K	Buy	413 +283	+218%	+$2.28K	﹤0.01%	2951
2026 Q1	$1.19K	Buy	130 +21	+19%	+$295	﹤0.01%	3072
2025 Q4	$1.74K	Buy	109 +70	+179%	+$2.04K	﹤0.01%	3081
2025 Q3	$1.82K	Sell	39 -4	-9%	-$147	﹤0.01%	2993
2025 Q2	$1.26K	Sell	43 -174	-80%	-$4.73K	﹤0.01%	3025
2025 Q1	$5.58K	Sell	217 -185	-46%	-$4.56K	﹤0.01%	2109
2024 Q4	$11.6K	Buy	402 +362	+905%	+$11K	﹤0.01%	2098
2024 Q3	$950	Buy	+40	New	+$888	﹤0.01%	2558

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Sterling Capital Management's LENZ Position: Q2 2026 in Review

Sterling Capital Management increased its LENZ Therapeutics (LENZ) stake by 218% in Q2 2026, buying an estimated $2.28K and bringing the position to 413 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #2951.

Sterling Capital Management first reported a position in LENZ in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.6K in Q4 2024. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Sterling Capital Management held 413 shares of LENZ Therapeutics worth $2.35K as of Q2 2026.
Sterling Capital Management bought 283 LENZ Therapeutics shares in Q2 2026, an estimated $2.28K.
LENZ Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2951 holding.
Sterling Capital Management first reported a position in LENZ Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's LENZ Therapeutics position peaked at $11.6K in Q4 2024.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.